FDA Warning Letter addressed to a Manufacturer of Medicinal Products in Hong Kong
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The FDA sent a warning letter to a manufacturer of medicinal products in Hong Kong on 15 December 2015. This warning letter criticises among others the following points which occurred during an FDA inspection taking place in July 2015:
- In the finished medicinal products identity and strength of the active ingredient were not tested.
- The identity of active ingredients and excipients from various suppliers was not verified.
- There was no data available on the control of stability.
- There didn't exist written procedures for production and process controls, including validation protocols and reports.
- There were neither written SOPs for the responsibilities nor for the review of out-of-specification results or for the handling of customer complaints.
- Evidence of regular calibration was missing for the scale in the production area.
- Multiple batches were released, despite a variety of deviations.
The FDA has not received a response from the firm concerning CAPA measures. As a result, the firm was now placed on Import Alert with immediate effect.
You will find more details in the complete FDA Warning Letter to Chan Yat Hing Medicines Factory.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods